Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Efanesoctocog Alfa vs rFVIII Products in Severe Haemophilia A
NCT06579144Phase 1Completed
- Sponsor
- Sobi
- Start
- Feb 2025
- Primary completion
- May 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of efanesoctocog alfa in hemophilia A (2 arms), sponsored by Sobi. Primary endpoint: Half-life at 14 days. Started Feb 2025; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06579144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06579144.